This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2016 Feb;15(2):81-2.

doi: 10.1038/nrd.2016.3.

Combination therapies in oncology

Rachel M Webster¹

Affiliations

PMID: 26837588
DOI: 10.1038/nrd.2016.3

Combination therapies in oncology

Rachel M Webster. Nat Rev Drug Discov. 2016 Feb.

. 2016 Feb;15(2):81-2.

doi: 10.1038/nrd.2016.3.

Author

Rachel M Webster¹

Affiliation

¹ Decision Resources, 9 Appold Street, London EC2A 2AP, UK.

PMID: 26837588
DOI: 10.1038/nrd.2016.3

No abstract available

PubMed Disclaimer

Similar articles

Highlights from the 29th European Society for Medical Oncology Congress: Vienna, Austria, October 29 through November 2, 2004.
Price N. Price N. Clin Prostate Cancer. 2004 Dec;3(3):136-40. Clin Prostate Cancer. 2004. PMID: 15636678 No abstract available.
[Oncology. The path to a pathogenesis-oriented treatment].
Hiddemann W. Hiddemann W. Dtsch Med Wochenschr. 1999 Dec 23;124(51-52):1562-5. Dtsch Med Wochenschr. 1999. PMID: 10664657 German. No abstract available.
The phase III candidate: can we improve the science of selection?
Bajorin D. Bajorin D. J Clin Oncol. 2004 Jan 15;22(2):211-3. doi: 10.1200/JCO.2004.10.988. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665614 No abstract available.
Malignant mesothelioma. Medical oncology: standards, new trends, trials--the French experience.
Bard M, Ruffié P. Bard M, et al. Lung Cancer. 2004 Aug;45 Suppl 1:S129-31. doi: 10.1016/j.lungcan.2004.04.023. Lung Cancer. 2004. PMID: 15261446 Review.
Monoclonal antibodies for medical oncology: a few critical perspectives.
Belda-Iniesta C, Ibáñez de Cáceres I, de Castro J. Belda-Iniesta C, et al. Clin Transl Oncol. 2011 Feb;13(2):84-7. doi: 10.1007/s12094-011-0623-z. Clin Transl Oncol. 2011. PMID: 21324795 Review.

See all similar articles

Cited by

Antibody-drug conjugates: beyond current approvals and potential future strategies.
Menon S, Parakh S, Scott AM, Gan HK. Menon S, et al. Explor Target Antitumor Ther. 2022;3(2):252-277. doi: 10.37349/etat.2022.00082. Epub 2022 Apr 28. Explor Target Antitumor Ther. 2022. PMID: 36046842 Free PMC article. Review.
GBM Drug Bank-a new resource for glioblastoma drug discovery and informatics research.
Svensson F, Westerman B, Würdinger T, Bailey D. Svensson F, et al. Neuro Oncol. 2018 Nov 12;20(12):1680-1681. doi: 10.1093/neuonc/noy122. Neuro Oncol. 2018. PMID: 30137543 Free PMC article. No abstract available.
Evaluation of synergism in drug combinations and reference models for future orientations in oncology.
Duarte D, Vale N. Duarte D, et al. Curr Res Pharmacol Drug Discov. 2022 May 12;3:100110. doi: 10.1016/j.crphar.2022.100110. eCollection 2022. Curr Res Pharmacol Drug Discov. 2022. PMID: 35620200 Free PMC article. Review.
Application of network link prediction in drug discovery.
Abbas K, Abbasi A, Dong S, Niu L, Yu L, Chen B, Cai SM, Hasan Q. Abbas K, et al. BMC Bioinformatics. 2021 Apr 12;22(1):187. doi: 10.1186/s12859-021-04082-y. BMC Bioinformatics. 2021. PMID: 33845763 Free PMC article.
Five-Feature Model for Developing the Classifier for Synergistic vs. Antagonistic Drug Combinations Built by XGBoost.
Ji X, Tong W, Liu Z, Shi T. Ji X, et al. Front Genet. 2019 Jul 9;10:600. doi: 10.3389/fgene.2019.00600. eCollection 2019. Front Genet. 2019. PMID: 31338106 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations